A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.

被引：0
|
作者：
Li, Ningning
Ge, Yuping
Wang, Xiang
Qiu, Wei
Zhang, Zhiyang
Zhou, Na
Zhao, Lin
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-374; 283-424-6846-271-2644; 298-145-222-7468; 261-566-148; 130-540-543-4790; 613-135-244-3829-325; 261-492-2769; 4; 3; 2; 2461; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [21] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
    Mohri, Kunihide
    Nagai, Hidenari
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
  • [22] EFFICACY OF GEMCITABINE AS SECOND-LINE THERAPY AFTER FAILURE OF S-1 THERAPY FOR METASTATIC PANCREATIC CARCINOMA
    Fukahori, M.
    Kondo, S.
    Ueno, H.
    Shimizu, S.
    Mitsunaga, S.
    Ikeda, M.
    Yamaguchi, T.
    Sakamoto, Y.
    Morizane, C.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 123 - 123
  • [23] Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
    Su Jin Lee
    Sungmin Kim
    Moonjin Kim
    Jeeyun Lee
    Yeon Hee Park
    Young-Hyuck Im
    Se Hoon Park
    BMC Cancer, 15
  • [24] Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
    Lee, Su Jin
    Kim, Sungmin
    Kim, Moonjin
    Lee, Jeeyun
    Park, Yeon Hee
    Im, Young-Hyuck
    Park, Se Hoon
    BMC CANCER, 2015, 15
  • [25] Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma
    Fukahori, Masaru
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [26] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Jin Li
    Zhendong Chen
    Yuxian Bai
    Bo Liu
    Qingshan Li
    Jingdong Zhang
    Jun Zhou
    Ting Deng
    Fuyou Zhou
    Shegan Gao
    Shujun Yang
    Feng Ye
    Long Chen
    Wei Bai
    Xianli Yin
    Shundong Cang
    Lianke Liu
    Yueyin Pan
    Hui Luo
    Yanxia Ji
    Zhen Zhang
    Jufeng Wang
    Quanliang Yang
    Na Li
    Rong Huang
    Chenglin Qu
    Jing Ni
    Bo Wang
    Yan Xu
    Jin Hu
    Qingmei Shi
    Jason Yang
    Nature Medicine, 2024, 30 : 740 - 748
  • [27] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Li, Jin
    Chen, Zhendong
    Bai, Yuxian
    Liu, Bo
    Li, Qingshan
    Zhang, Jingdong
    Zhou, Jun
    Deng, Ting
    Zhou, Fuyou
    Gao, Shegan
    Yang, Shujun
    Ye, Feng
    Chen, Long
    Bai, Wei
    Yin, Xianli
    Cang, Shundong
    Liu, Lianke
    Pan, Yueyin
    Luo, Hui
    Ji, Yanxia
    Zhang, Zhen
    Wang, Jufeng
    Yang, Quanliang
    Li, Na
    Huang, Rong
    Qu, Chenglin
    Ni, Jing
    Wang, Bo
    Xu, Yan
    Hu, Jin
    Shi, Qingmei
    Yang, Jason
    NATURE MEDICINE, 2024, 30 (03) : 740 - 748
  • [28] A global perspective in second-line treatment patterns for patients with advanced esophageal squamous cell carcinoma
    Jaffe, Dena H.
    Gricar, Joseph
    DeCongelio, Marc
    Mackie, DeMauri S.
    THORACIC CANCER, 2022, 13 (09) : 1240 - 1257
  • [29] Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
    Kaur, G.
    Rai, P.
    Singh, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1476 - S1476
  • [30] Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma
    Alsina, Maria
    Fleitas-Kanonnikoff, Tania
    MED, 2024, 5 (09): : 1038 - 1040
12345